Interdigitating reticulum cells in lymph nodes of Sézary syndrome

1987 ◽  
Vol 54 (1) ◽  
pp. 221-231 ◽  
Author(s):  
E. Kaiserling ◽  
H. Wolburg
Keyword(s):  
Lymph Nodes ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Interdigitating Reticulum Cells ◽  
Reticulum Cells

scholarly journals Expression of Thymidine Phosphorylase in Lymph Nodes Involved with Mycosis Fungoides and Sézary Syndrome

2011 ◽  
Vol 2011 ◽  
pp. 1-6
Author(s):  
Xingcao Nie ◽  
Rekha Bhat ◽  
Essel Dulaimi Al-Saleem ◽  
Eric C. Vonderheid ◽  
J. Steve Hou
Keyword(s):  
T Cells ◽  
T Cell ◽  
Lymph Nodes ◽  
Mycosis Fungoides ◽  
Thymidine Phosphorylase ◽  
Cell Transformation ◽  
Large Cell ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Thymidine Phosphorylase Expression

Thymidine phosphorylase may be overexpressed in both neoplastic cells and tumor stromal cells in a variety of malignancies. Our study explores thymidine phosphorylase expression in lymph nodes (LNs) from patients with mycosis fungoides (MF) or Sézary syndrome (SS). In MF/SS, the LNs may have a pathologic diagnosis of either dermatopathic lymphadenopathy (LN-DL) or involvement by MF/SS (LN-MF). We performed immunohistochemical staining on MF/SS lymph nodes using antibodies to thymidine phosphorylase, CD68, CD21, CD3, and CD4. In both LN-DL and benign nodes, thymidine phosphorylase staining was noted only in macrophages, dendritic cells, and endothelial cells. In LN-MF, thymidine phosphorylase expression was also noted in subsets of intermediate to large neoplastic T cells. Concurrent CD68, CD21, CD3, and CD4 staining supported the above observations. Similar results were noted in the skin and in LN-MF with large cell transformation. Other T-cell lymphomas were also examined (total 7 cases); only enteropathy-type T-cell lymphoma (1 case) showed TP positivity in neoplastic T lymphocytes. We demonstrated that thymidine phosphorylase staining is present in neoplastic T cells in mycosis fungoides. The exact mechanism needs further investigation.

A histologic study of lymph nodes from patients with the sézary syndrome

Cancer ◽  
1986 ◽  
Vol 57 (12) ◽  
pp. 2375-2380 ◽  
Author(s):  
E. Scheffer ◽  
C. J. L. M. Meijer ◽  
W. A. Van Vloten ◽  
R. Willemze
Keyword(s):  
Lymph Nodes ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Histologic Study

scholarly journals FoxP3-Positive T-Regulatory Cells in Lymph Nodes with Mycosis Fungoides and Sézary Syndrome

Lymphoma ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Rekha Bhat ◽  
Bhavna Khandpur ◽  
Eric C. Vonderheid ◽  
J. Steve Hou
Keyword(s):  
T Cells ◽  
T Cell ◽  
Regulatory T Cells ◽  
Lymph Nodes ◽  
Mycosis Fungoides ◽  
Cox Proportional Hazards Model ◽  
Cell Phenotype ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Malignant T Cells

Mycosis fungoides and Sézary syndrome are indolent cutaneous T-cell lymphomas, with skin-associated peripheral lymph nodes being the most frequent extracutaneous site of involvement. Acquisition of functional properties of regulatory T-cells by malignant T-cells in advanced disease may contribute to immunosuppression. Whereas previous studies examining FoxP3 protein expression in mycosis fungoides and Sézary syndrome have focused on skin specimens, little data are available on lymph nodes from patients with these conditions. In this study we examined FoxP3+ regulatory T-cells in lymph nodes from 26 patients with mycosis fungoides and Sézary syndrome and correlated the findings with clinical data, molecular assays for T-cell clonality, and flow cytometry. Except for one case of Sézary syndrome in which malignant T-cells expressed FoxP3 protein, a significantly lower number of FoxP3-expressing cells occurred in lymph nodes that were clearly involved with lymphoma as compared to uninvolved nodes. Cox proportional hazards model showed that lymph node rating and histological evidence of transformation, but not number of FoxP3+ cells, were factors significantly associated with adverse prognosis. We speculate that modulation of FoxP3+ cells in lymph nodes involved with lymphoma might play a role in disease progression. Attainment of a regulatory T-cell phenotype by a subset of lymphoma cells might signal a poor prognosis.

Altered expression of inflammasome on the skin and lymph nodes in Sézary syndrome

2019 ◽  
Vol 119 ◽  
pp. S21
Author(s):  
K.C.G. Manfrere ◽  
M.P. Torrealba ◽  
D.R. Miyashiro ◽  
J.A. Sanches ◽  
M.N. Sato
Keyword(s):  
Lymph Nodes ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Altered Expression

scholarly journals μ-Opioid Receptor Is Induced by IL-13 within Lymph Nodes from Patients with Sézary Syndrome

2010 ◽  
Vol 130 (5) ◽  
pp. 1337-1344 ◽  
Author(s):  
Alan Bénard ◽  
Pierre Cavaillès ◽  
Jérôme Boué ◽  
Emmanuelle Chapey ◽  
Jagadeesh Bayry ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Opioid Receptor ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Μ Opioid Receptor

scholarly journals Patterns of cell proliferation and cell migration in the Sezary syndrome

Blood ◽  
1981 ◽  
Vol 57 (3) ◽  
pp. 452-463
Author(s):  
PA Jr Bunn ◽  
R Edelson ◽  
SS Ford ◽  
SE Shackney
Keyword(s):  
Cell Proliferation ◽  
Cell Migration ◽  
Lymph Nodes ◽  
Peripheral Blood ◽  
Tritiated Thymidine ◽  
Cell Labeling ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Sézary Cells

The patterns of cell proliferation and cell migration were studied in three patients with the Sezary syndrome using autoradiographic techniques. Cell labeling patterns following pulse labeling with tritiated thymidine in vivo indicated that Sezary cells proliferate actively in skin and in lymph nodes but that few if any Sezary cells proliferate in the peripheral blood. In two of the patients serial samples were obtained. Label dilution patterns in skin and blood over time suggested that circulating Sezary cells originated in extracutaneous sites where cells were proliferating more rapidly than in the skin. Cells labeled in extracutaneous sites of proliferation appear rapidly in the blood, and their transit time through the peripheral blood compartment is short. Circulating Sezary cells may then be deposited in the skin where they resume proliferation at a low rate. Thus, while Sezary cells proliferate in both cutaneous and extracutaneous sites, proliferation appears to be more rapid in extracutaneous sites such as lymph nodes. This suggests that trials of systemic therapeutic approaches should be undertaken.

Sign in / Sign up

Export Citation Format

Share Document